Novacyt de volgende biotech raket!

12.382 Posts, Pagina: 1 2 3 4 5 6 ... 616 617 618 619 620 » | Laatste
Aantal posts per pagina:  20 50 100 | Omlaag ↓
BiotechParels
0
Gister was een bizarre dag want TxCell en BioPhytis gingen met meer dan 50% omhoog….op geen nieuws! Een combinatie van een lange dalende trend waarbij er opeens geen verkopers meer waren maar wel kopers! En bij Novacyt kan het volgende gebeuren. Bekijk de grafiek!
Bijlage:
ik ben Diede
0
nog steeds.
Laatste kapitaalbehoefte is volgens mij voldaan vorige week.
Dus nu terug naar de €1,50.
Hopen althans, want ik zit lekker long. :)
SJURVM
0
Novacyt reports storming sales start to 2017
Group sales increased 25 per cent on a reported basis and 38 per cent at constant exchange rates driven by NOVAprep® growth and the acquisition of Primerdesign.

The gross margin continued to improve and was up seven percentage points to 55 per cent. On a pro forma basis, the group achieved a further improvement in gross margin to 59 per cent.

Losses at the EBITDA level were reduced to €2.3 million (a loss of €1.7m on a pro forma basis) compared with a €2.9m loss for 2015. Momentum towards near-term EBITDA profitability was demonstrated by an EBITDA loss of €0.7m in H2 compared with €1.6m in H1.

Group CEO Graham Mullis (pictured) said: “I am delighted to report continued strong double-digit sales growth across the group in 2016. Our increased sales momentum reflects the acquisition of Primerdesign, a profitable high-growth molecular diagnostic business and successful investment in NOVAprep® commercial infrastructure.

“We have delivered the fourth consecutive period of high double-digit NOVAprep® sales growth. Consequently, our gross margin has continued to improve and I expect the trajectory to profitability to continue to accelerate, as demonstrated by the run-rate EBITDA loss significantly reduced during the second half of 2016.

“Furthermore, 2017 has started very strongly, with sales up over 70 per cent across the group and I look forward to updating our shareholders and the market of our continued progress during the year.”

www.businessweekly.co.uk/news/biomedt...
SJURVM
0
SJURVM
0
www.businesswire.com/news/home/201702...

The additional non-gynaecological approval in China for NOVAprep® brings the technology to multiple new cancer markets and reinforces our direct sales investment in China, which is already giving substantial growth of 100%+ in 2016 and is expected to deliver more in 2017. We reported strong 100%+ growth across the Asia Pacific region in 2016 and I look forward to updating our shareholders further with the progress we are making in the region during 2017
SJURVM
0
As always, before making an investment ,do your homework. Caveat Emptor and all that jazz
SJURVM
0
www.businesswire.com/news/home/201706...

Graham Mullis, Group CEO of Novacyt, commented:

“Momentum towards profitability has continued through H1 2017 and with the increased sales demand across the business we are pleased with progress in the Company’s financial performance. I look forward to updating shareholders of this financial progress in July 2017.
[verwijderd]
0
Chasse_Patate
0
quote:

PonziNL schreef op 19 september 2016 08:41:


Hou dit fonds in de gaten!


Zeg dat wel.
De beursdag voor jouw bericht was dit fonds gesloten op 1,40.
Nu staat het op 0,84, een verlies van 40%.
Absoluut een fonds om in de gaten te houden.
Op 13 juli hun revenue rapportage.
Ik ben benieuwd!

[verwijderd]
0
ik ben ook benieuwd, ze hebben 2 weken geleden nog geld opgehaald tegen 0.85 en de CEO zei dat die verheugd is over de resultaten.

Korotm, die zullen goed zijn en als dan de IPO ook nog eens een succes wordt sta je zo +100%
objectief
0
Ik heb voorlopig genoeg chasse_pataten gegeten in de biosector...eerst Galapagos en daarna MdxHealth. (ik laat deze kans aan mij voor gaan)
SJURVM
0
more than average share activity today
started yesterday in the afternoon


figures must be looking good :)
Chasse_Patate
0
quote:

SJURVM schreef op 21 juni 2017 13:14:


www.businesswire.com/news/home/201706...

Graham Mullis, Group CEO of Novacyt, commented:

“Momentum towards profitability has continued through H1 2017 and with the increased sales demand across the business we are pleased with progress in the Company’s financial performance. I look forward to updating shareholders of this financial progress in July 2017.


Graham Mullis looks forward to updating shareholders of this financial progress in July 2017.

Morgen de update.
Vandaag hopelijk de laatste kans om in te stappen op deze lage koers!

12.382 Posts, Pagina: 1 2 3 4 5 6 ... 616 617 618 619 620 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 7 apr 2020 09:21
Koers 2,515
Verschil +0,040 (+1,62%)
Hoog 2,550
Laag 2,370
Volume 1.737.757
Volume gemiddeld 14.346.613
Volume gisteren 14.917.949

Brussel real time stocks quotedata by Euronext. Other real time EU stocks, by Cboe Europe Ltd.; US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: VWD Group